This website is for US healthcare professionals only. This website is not intended for patients.

Logo Horizontal
  • For HCPs
    • Prescribing information
    • Coverage restrictions
    • Prior authorization
    • Financial assistance
    • Sample requests
  • For Practices
    • Practice collaboration
    • Rep Management
  • For brands
    • Claim your page
    • Brand activation
    • Rep Connect
  • About
  • For HCPs
    • Prescribing information
    • Coverage restrictions
    • Prior authorization
    • Financial assistance
    • Sample requests
  • For Practices
    • Practice collaboration
    • Rep Management
  • For brands
    • Claim your page
    • Brand activation
    • Rep Connect
  • About
Compare drug alternatives

Emgality® Alternatives

Emgality®

(Galcanezumab)
Emgality
    Migraine
  • Vyepti®
  • Ajovy®
  • Nurtec ODT®
  • Ubrelvy®
  • Qulipta®
Prescription Only
Emgality is a medication that can be self-administered once a month by injecting it subcutaneously under the skin. It is used for migraine prevention in adults and can also be used to treat cluster headaches during a cluster headache period. The most frequently reported side effect is injection site reactions. Additionally, there are no known drug interactions with Emgality. Emgality is FDA approved for the following indications: Migraine and Cluster Headaches.

Aimovig®

(Erenumab)
Aimovig
    Migraine
  • Vyepti®
  • Ajovy®
  • Nurtec ODT®
  • Ubrelvy®
  • Qulipta®
Prescription Only
Aimovig is a prescription medication that adults can self-inject once a month under the skin to prevent migraine headaches. The most common side effects are injection site reactions and constipation. However, there are no reported instances of drug interactions with Aimovig. Aimovig is FDA approved for the following indications: Migraine prevention.

Dosage & Administration

Administration
Subcutaneous
Subcutaneous
Dosing
Migraine: 240 mg loading dose (120 mg x 2) followed by 120 mg monthly.
70 mg once monthly or 140 mg once monthly (for some patients)
Latin Shorthand
240 mg LD (120 mg x 2) then 120 mg/mo.
70 mg/mo or 140 mg/mo

Financial Assistance

Copay
$0
$5
Annual Cap
$4,900
Patient specific maximum benefit.
Assistance Expiration
12 months
Calendar year
Generics
No lower-cost generic available
No lower-cost generic available

Popular alternatives

  • Emgality® vs. Vyepti®
  • Emgality® vs. Ajovy®
  • Emgality® vs. Nurtec odt®
  • Emgality® vs. Ubrelvy®
  • Emgality® vs. Qulipta®

Relevant Resources

Emgality
  • Dosage & Administration
  • Drug Label
  • Samples
  • Prior Authorization
  • Financial Assistance
Aimovig
  • Dosage & Administration
  • Drug Label
  • Samples
  • Prior Authorization
  • Financial Assistance
Company
About
Careers
Privacy
Terms
Contact
Solutions
Prescribing Information
Coverage Restrictions
Prior Authorization
Financial Assistance
Sample Requests
Practice Collaboration
Rep Management
Indications
Most Viewed
Angioedema
Atopic Dermatitis
Plaque Psoriasis
Psoriatic Arthritis
Rosacea
Compare drug alternatives
Providers
Log in
Sign up
Request demo
© PrescriberPoint, Inc. 2023. Help Patients, Increase Practice Efficiency.